Nociscan is the primary augmented intelligence platform to measure ache biomarkers within the lumbar spine
This new product launch expands accessibility of Nociscan on the worldwide MR market
Builds on preexisting compatibility with Siemens
BROOMFIELD, CO, Jan. 17, 2024 (GLOBE NEWSWIRE) — by way of NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare know-how firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the placement of persistent low again ache (cLBP), introduced as we speak the product launch of Nociscan 2.6 which incorporates help for added main magnetic resonance imaging (MRI) scanners. With this product launch Nociscan can now be carried out on MRI machines past these manufactured by Siemens.
“This necessary technical milestone expands Nociscan entry to healthcare suppliers and sufferers all through the world in a really important means,” acknowledged Brent Ness, CEO of Aclarion. “One of many key catalysts we’ve inspired traders to give attention to is MRI activations for our key opinion chief surgeons and different surgeons all for utilizing Nociscan of their surgical decisioning course of. MRI compatibility with Nociscan has been traditionally restricted to machines manufactured by Siemens. Though Siemens is a serious participant within the MRI market, we is not going to relaxation till Nociscan is accessible on the main MRI machines of all producers. The two.6 product launch is a serious milestone towards this goal and can facilitate close to time period surgeon activations in markets we’ve needed to throttle till now.”
The development of augmented intelligence resolution help options, like Nociscan, is quickly enhancing the lives of tens of millions of sufferers. Aclarion is honored to be main the business in addressing a world healthcare downside that impacts roughly 266 million individuals who endure from degenerative spine illness and low again ache.
“Aclarion’s mission is to alter the paradigm in spinal diagnostics and for Nociscan to change into the usual resolution help instrument used to diagnose and deal with persistent low again ache,” mentioned Ryan Bond, Chief Technique Officer. “Including capability for Nociscan has been a part of our technique, and we’re happy with this growth, which advances our journey to straightforward of care.”
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages magnetic resonance spectroscopy, proprietary sign processing methods, biomarkers, and augmented intelligence algorithms to optimize medical remedies. The Firm is first addressing the persistent low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By way of a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing methods extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan supplies vital insights into the placement of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra info, please go to www.aclarion.com.
This press launch comprises forward-looking statements inside the that means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 in regards to the Firm’s present expectations about future outcomes, efficiency, prospects, and alternatives. Statements that aren’t historic info, resembling “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are based mostly on the present plans and expectations of administration and are topic to a variety of uncertainties and dangers that might considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Trade Fee. Readers are inspired to assessment the part titled “Threat Components” within the Firm’s Annual Report on Kind 10-Okay for the 12 months ended December 31, 2022, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Trade Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
Kirin M. Smith
PCG Advisory, Inc.